Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1991-02-13
1993-05-04
Tsang, Cecilia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514176, 514177, 514178, 514179, 514181, 514182, 540 95, 540 96, 540 97, 540 94, 540 99, 540106, 540107, 540108, 540109, 540110, 540111, 540112, 540113, 540114, 540120, A61K 3158, A61K 3156, C07J 4300, C07J 4100
Patent
active
052082270
ABSTRACT:
Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-ammobutyric acid/benzodiazepine receptor-chloride ionophore (GBR) complex.
REFERENCES:
patent: 4203981 (1980-05-01), Pierdet et al.
patent: 4213978 (1980-07-01), Bodor et al.
patent: 4268441 (1981-05-01), Bodor et al.
patent: 4415554 (1983-11-01), Horrobin
patent: 4447424 (1984-05-01), Teutsch et al.
patent: 4605649 (1986-08-01), Liehr
patent: 4634693 (1987-01-01), Cardarelli et al.
patent: 4681875 (1987-07-01), Laurent et al.
patent: 4774236 (1988-09-01), Cook et al.
Mattson et al, Advance in Epileptology=XV+R Epilepsy Int'l Symposium. 279-82 (1984).
Majewska et al, Science 232: 1004-7 (1986).
Harrison, et al. J. Pharmcol. Exp. Ther. 241:346-53 (1987).
Backstrom et al, Acta Obstet. Gynecol. Scand. Suppl. 130:19-24 (1985).
Pfaff et al, Science 219:808-14 (1983).
Gyermac, et al, J. Med. Chem. 11:117 (1968).
Dalton, K. Premenstrual Syndrome & Progesterone Therapy 13-26 (2nd Ed. 1984).
Laidlaw; J. Lancet. pp. 1235-1237 (Dec. 15, 1956).
Rosciszewska et al. J. Neurol. Neurosurg. Psych. 19:47-51 (1986).
Backstrom et al, Acta Endocr. Suppl. 256-257 (1983).
Maddocks et al, J. Obstet. Gynecol. 154:573-81 (1986).
Dennerstein et al, British Medical Journal 290:16-7 (1985).
Bodor, N., Drugs of the Future, 6(3):165-182, 1981.
Bodor, J. Pharmaceutical Sciences, 73(3):385-389, 1984.
Gee, K. W. et al., in Drugs In Central Nervous System Disorders, pp. 123-147, D. C. Horvell, ed., 1985.
Gee, K. W. et al., European Journal of Pharmacology, 136:419-423, 1987.
Gee, K. W. et al., Molecular Pharmacology, 30:218-225, 1986.
Gyermek, L., et al., J. Med. Chem., 11:117-125, 1968.
Lawrence, L. J. et al., Biochem. Biophys. Res. Comm., 123:1130-1137, 1984.
Maksay, G. et al., J. Neurochem., 44:480-486, 1985.
Marker, R. E. et al., J. Am. Chem. Soc. 59, 616-618, 1937.
Marrian, G. F., et al., Biochem., 40:376-380, 1946.
Notari, R. E., Methods in Enzymology, 112:309-323 (1985).
Squires, R. F., et al., Mol. Pharmacol., 23:326-336, 1983.
Swinyard, E. A., et al., in Antiepileptic Drugs, D. M. Woodbury, J. K. Penry and C. E. Pippenger, eds., p. 111 (Raven Press, New York), 1982.
Wood, P. L., et al., J. Pharmacol. Exp. Ther., 231:572-576, 1984.
Worms, P., et al., J. Pharmacol, Exp. Ther., 220:660-671, 1982.
Bolger Michael B.
Brinton Roberta E.
Burke Deborah J.
Gee Kelvin W.
McEwen Bruce S.
Tsang Cecilia
University of Southern California
LandOfFree
Method, compositions, and compounds for modulating brain excitab does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method, compositions, and compounds for modulating brain excitab, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method, compositions, and compounds for modulating brain excitab will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1975293